ZG16

Across TCGA pan-cancer cohorts, ZG16 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZG16 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZG16 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZG16 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ZG16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.600	0.288	.004	14	view →
LUAD	DFS	Median	II,III,IV	0.123	0.826	.006	13	view →
LSCC	DFS	Median	II,III,IV	1.000	0.575	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZG16–PDAC (DFS)

Open the PDAC breakdown →